No savings at 50? I’d buy these 2 FTSE 100 stocks to retire on a rising passive income

These two FTSE 100 (INDEXFTSE:UKX) dividend heroes could make your retirement more comfortable.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you haven’t built up much in the way retirement savings at age 50, you need to start playing catch-up today. I think the best way of doing this is to invest in equities using your annual Stocks and Shares ISA allowance.

This allows you to invest anything up to £20k in the stock market before 5 April, with all returns free of tax. I would start by investing in a balanced portfolio of FTSE 100 shares to generate growth and income. These two could be a good place to start.

GlaxoSmithKline

Pharmaceutical company GlaxoSmithKline (LSE: GSK) is a giant of a stock, with a market-cap of more than £92bn. Its three global businesses focus on pharmaceuticals, vaccines and consumer healthcare and spends around £4bn a year researching and developing a pipeline of new products, to keep the cash and profits flowing.

The Glaxo share price is now in revival mode, as I predicted this time last year, when I hailed it the ideal buy for uncertain times. It’s up around 25% since then.

Glaxo’s stock offers a solid dividend yield of around 4.3% a year, so the total return over the last year was closer to 30%. Despite that, it still looks a relative bargain, as its shares trade at around 15.3 times earnings, below the FTSE 100 average of 18.03 times.

Glaxo has frozen its dividend at around 80p in recent years, to pump more of its profits into R&D. Investors are now waiting to see whether that investment is going to pay off. The share price may not rise another 25% this year, but if investing for retirement, you have to look beyond that.

At age 50, you could hold this stock for another 30 years or so, and over such a lenghty period I believe GlaxoSmithKline will prove a rewarding investment for both growth and income.

Legal & General Group

Here’s another renowned FTSE 100 blue-chip stock I’d consider to generate a passive income. Asset manager and insurer Legal & General Group (LSE: LGEN) offers an even more generous yield than Glaxo, with a forecast income of 6.2% in the year ahead.

This is far above the FTSE 100 average of 4.34% and, crucially, it also looks sustainable, as it’s covered 1.8 times by company earnings.

The last 12 months have also been good for the Legal & General share price, which is up more than 20%. It’s enjoyed growth from the bulk annuity market, insuring risk on company pension schemes to ease the burden on employers.

The £18.62bn group has an incredible £1.2trn of assets under management, making it one of Europe’s biggest fund managers, yet trades at a bargain price of just 9.4 times earnings. You can buy the L&G share price for just half the FTSE 100’s valuation.

If equities have a bumpy year I’d seize the opportunity to load up on more L&G stock at the lower price, as part of your quest to build a portfolio of shares to deliver a rising passive income when you retire.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British pound data
Investing Articles

The red lights are flashing again for Lloyds’ share price! Here’s why

Lloyds' share price continues to defy gravity. But Royston Wild thinks it's only a matter of time before the FTSE…

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

Aston Martin shares are now only 41p!

Aston Martin shares just dropped to around the 41p mark! Is this a brilliant buying opportunity or a stock that…

Read more »

Artillery rocket system aimed to the sky and soldiers at sunset.
Investing Articles

Up 325% in 5 years! But are BAE System shares still a no-brainer buy?

BAE Systems shares would have been a brilliant buy five years ago. But could they still offer excellent returns if…

Read more »

Investing Articles

How much do you need to invest each month into FTSE 100 shares to aim for a million?

Simply by putting a few hundred pounds a month into FTSE 100 shares, how might someone aim to become a…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

£10,000 invested in BAE shares at the beginning of 2026 is now worth…

Paul Summers tips his hat to those who invested in BAE Systems shares when markets opened back up in January.…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

What size ISA do you need for £250-a-week retirement income?

Harvey Jones outlines the advantages of investing in a Stocks and Shares ISA rather than leaving money in cash, and…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

£5,000 invested in Legal & General shares 5 years ago is now worth…

Harvey Jones crunches the numbers to show how much an investor would have earned from Legal & General shares lately,…

Read more »

Investing Articles

Just check out the latest bumper forecasts for Lloyds, NatWest and Barclays shares

Harvey Jones says Barclays shares have had a terrific year and there could be more action to come. So what's…

Read more »